Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Completes Acquisition of Lark

NEW YORK , April 2 (GenomeWeb News) - Genaissance Pharmaceuticals and Lark Technologies announced yesterday that the planned acquisition of Lark by Genaissance has been completed.


The deal closed after stockholders from both companies approved the plan. As part of the terms of agreement, each outstanding share of Lark's common stock will be exc han ged for 1.81 shares of Genaissance stock.


Genaissance announced its plan in December to acquire Lark for $19.9 million.


The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.